Cargando…

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

BACKGROUNDS: Remarkable interindividual variability in clopidogrel response is observed, genetic polymorphisms in P2RY12 and its signal pathway is supposed to affect clopidogrel response in CHD patients. METHODS: 539 CHD patients treated with clopidogrel were recruited. The platelet reaction index (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yan-Jiao, Li, Dong-Jie, Li, Zhong-Yi, Hu, Xiao-Lei, Li, He, Ma, Qi-Lin, Chen, Xiao-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801627/ https://www.ncbi.nlm.nih.gov/pubmed/36581799 http://dx.doi.org/10.1186/s12872-022-02988-w

Ejemplares similares

Association of N6AMT1 rs2254638 Polymorphism With Clopidogrel Response in Chinese Patients With Coronary Artery Disease
por: Li, He, et al.
Publicado: (2018)

Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel
por: Zhong, W‐P, et al.
Publicado: (2017)

Influence of GAS5/MicroRNA‐223‐3p/P2Y12 Axis on Clopidogrel Response in Coronary Artery Disease
por: Liu, Yan‐Ling, et al.
Publicado: (2021)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)
por: Akkaif, Mohammed Ahmed, et al.
Publicado: (2021)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
por: Kitazono, Takanari, et al.
Publicado: (2018)

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
por: Neubauer, Horst, et al.
Publicado: (2011)

Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention
por: Adamiak-Giera, Urszula, et al.
Publicado: (2020)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Mapping the antiplatelet effects of clopidogrel and aspirin by modified thromboelastography
por: Hemlata,, et al.
Publicado: (2013)

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
por: Li, Yi, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
por: Zhang, Yan-Jiao, et al.
Publicado: (2017)

Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease
por: Tresukosol, Damrus, et al.
Publicado: (2014)

Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers
por: Seo, Kwon-Duk, et al.
Publicado: (2014)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
por: Amin, Arwa M., et al.
Publicado: (2017)

PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease
por: Li, Ke-Cheng, et al.
Publicado: (2017)

A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease
por: Zhang, Zhaojian, et al.
Publicado: (2019)

Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention
por: Gao, Song-Tao, et al.
Publicado: (2023)

Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers
por: Lee, Wonjae, et al.
Publicado: (2010)

Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials
por: Xu, Lei, et al.
Publicado: (2016)

Effect of Dialysis on Antiplatelet Drug Efficacy in Uremic Patients with Coronary Heart Disease
por: Fu, Dong-Liang, et al.
Publicado: (2017)

Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
por: Kim, Dong-Yeon, et al.
Publicado: (2021)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
por: Qu, Jianyu, et al.
Publicado: (2021)

CD80 DNA methylation and single-nucleotide polymorphism associated with clopidogrel response: a whole-genome DNA methylation analysis in acute coronary syndrome
por: Song, Pei-Yuan, et al.
Publicado: (2023)

Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study
por: Yao, Ying, et al.
Publicado: (2019)

Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel
por: Gu, Ruo-Xi, et al.
Publicado: (2016)

Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis
por: Luo, Xiaofeng, et al.
Publicado: (2023)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
por: Zhuo, Xiaojun, et al.
Publicado: (2018)

Postoperative Bleeding Risk for Oral Surgery under Continued Clopidogrel Antiplatelet Therapy
por: Gröbe, Alexander, et al.
Publicado: (2015)

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
por: Cirillo, Plinio, et al.
Publicado: (2020)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment
por: Kang, Hyun Goo, et al.
Publicado: (2021)

Analysis of Gastrointestinal Prophylaxis in Patients Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Morneau, Kathleen M., et al.
Publicado: (2014)

Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results
por: Chen, Yue-Xin, et al.
Publicado: (2015)

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
por: Obayashi, Yuki, et al.
Publicado: (2022)

Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
por: Marcano, Ana Lucrecia, et al.
Publicado: (2022)

Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors
por: Ristorto, Jessica, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4luiv837t530kvnpeut9dd6g2h